Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of the combined
treatment of Sorafenib (BAY 43-9006) with Gemcitabine and radiotherapy in patients with
localized unresectable pancreatic cancer.